Nuevocor Doses First Patient in SUNBEAM-LMNA Phase 1/2 Trial and Receives FDA Fast Track Designation for NVC-001 in LMNA Dilated Cardiomyopathy

01 THE MACHINE READ

WHY IT MATTERS.

First patient dosing plus FDA Fast Track in a private gene-therapy trial is clinical progress without listed exposure.

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

04 RECEIPTS

THE SOURCE RECORD.

05 PROPAGATION

WHAT THIS TOUCHES.